Predicting a better future - Chris Viehbacher, Chief Executive Officer of Sanofi-aventis.

At the Financial Times Global Pharmaceutical and Biotech Conference this week, the keynote address was given by M. Chris Viehbacher, Chief Executive Officer of Sanofi-aventis.


In the context of global financial meltdown, three industry mega mergers, and the usual challenges facing Big Pharma it was bound to be interesting to hear the perspective of an industry heavyweight such as Chris, who prior to Sanofi-aventis, was a member of the board of GSK, and President of its Pharmaceutical Operations in North America.

And what he thinks certainly will matter to Sanofi-aventis. As he describes the role of CEO Youve got your hands on the wheel, and you decide where to go. Having been quoted in Forbes Magazine in its most recent issue, "Betting the farm and waiting for the next blockbuster is not going to work," in his FT keynote, Chris commented that whilst there was low growth for the industry in traditional markets, there was growth to be seen in emerging and non-traditional markets, and new models to explore, supported by a number of consumer mega-trends:


An ageing population
Increasing propensity of obesity and diabetes
Increasing urbanization creating greater demand for medical services
Well being factors like aesthetics and nutrition
Time compression, and
Communications and information technology
With this in mind, it was not surprising to see that he sees growth drivers for Sanofi-aventis including vaccines, diabetes, emerging markets, and OTC/OTX. In a sentence, Chris predicted A much better next decade than the one weve just experienced.

Category:

Science & Technology

Tags:

• PharmiWeb
• Sanofi
• Chris Viehbacher
• Sanofi-aventis
• Pharma

[ShirleyLedlie]

You might like to explain why Sanofi Aventis continue to lie about the incidences of the adverse side effect that Taxotere causing permanent hair loss. The last study showed it was 6.3% which is alot higher than 0.01% that Sanofi claim as they keep telling everyone they disfugure thats its very rare. Actually Sanofi it common and frequent.

Mr Viehbacher didnt reply to my letter either. Instead he passed my letter onto someone else to answer who just tried to fobb me off.